Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Immune-checkpoint inhibitors for urothelial cancer

Petros Grivas, MD, PhD, of the Seattle Cancer Care Alliance, Seattle, WA, discusses the benefits immune-checkpoint inhibitors bring in the treatment of urothelial cancer. Dr Grivas also discusses pipelined research and other promising agents. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.